The Quadrivalent Influenza Vaccine developed by the Hualan Bio this time contains the above two influenza A and two influenza B antigens, covering more influenza epidemic types, which will effectively prevent and control influenza epidemic.
Hualan Genetic Engineering Co. Ltd received the new drug application acceptance notice of " Recombinant Anti- CTLA-4 Human Monoclonal Antibody Injection" issued by China Food and Drug Administration.
Group AC Meningococcal Polysaccharide Vaccine of Hualan Biological Bacterin Co., Ltd Passing GMP
Shengming Bio is wholly owned subsidiary of Hualan Group and can provide CRO and CMO services related to monoclonal antibody drugs that fully meet the requirements of CFDA/FDA.
Hualan Bio, 2018 CSITF Exhibition, Biological Medicine, Plasma Products, Vaccine Products
Recommended composition of influenza virus vaccines for use in the 2018-2019 northern hemisphere influenza season
According to the latest FluView report, Influenza activity increased again in USA. The overall hospitalization rate is higher than the overall hospitalization rate reported during the same week of the 2014-2015 season; the most severe season in recent years.
More and More People Die of Respiratory Diseases Linked to Seasonal Flu, Inactivated Influenza Vaccine(Split Virion) of Hualan Bio Passed WHO PQ, and Win Great Reputation from UNICEF.